Rachel Y. Ames,Rongqi Zhao,Parker Mace,Adam Grant,Guorui Xie,Heather Milestone,Molly Grandcolas,Eva Fang,Nicolae Kiosea,Stephen Wong,Martin Brovarney,Scott Jacobson,Danilo Nebalasca,Jorge Arguello,Blanca Gomez,Hiranmayee Kandala,Michelle Y. Ko,Lan Nguyen,Omar Robles,Grant Shibuya,Anton A. Shakhmin,Parcharee Tivitmahaisoon,Vi-Anh Vu,Ashkaan Younai,Mikhail Zibinsky,Babu Subramanyam,Daniel Poon,Mohsen Sabouri Ghomi,David J. Wustrow,Paul D. Kassner,George E. Katibah,Dirk G. Brockstedt

Abstract:Abstract Hematopoietic progenitor kinase 1 (HPK1) has been shown to act as a negative regulator of T cell receptor signaling and of subsequent effector T cell function. Inhibiting HPK1 to enhance T cell activity has emerged as a promising strategy for cancer immunotherapy. Upon T cell receptor engagement, the kinase domain of HPK1 is activated and targets components of the T cell receptor (TCR) signaling pathway for degradation, including SLP76. However, the molecular events connecting HPK1 kinase activity to observed T cell functions downstream of proximal TCR signaling are not well understood. Through transcriptional profiling of HPK1-kinase-dead (HPK1-KD) versus wild-type CD8+ T cells following an acute, attenuated Listeria monocytogenes infection, we observed increased expression of many genes associated with T cell activation and effector function, including changes in expression of several key transcription factors and their targets. Upon activation, HPK1-KD T cells, as well as T cells treated with our small-molecule HPK1 inhibitor, produce higher levels of a wide range of effector cytokines in vitro and in vivo. Treatment of mice with the HPK1 inhibitor also inhibited tumor growth in several syngeneic tumor models. These data expand our understanding of the role of HPK1 in inhibiting CD8+ T cell effector programs, and, importantly, the impact of HPK1 inhibitors on T cell function. Citation Format: Rachel Y. Ames, Rongqi Zhao, Parker Mace, Adam Grant, Guorui Xie, Heather Milestone, Molly Grandcolas, Eva Fang, Nicolae Kiosea, Stephen Wong, Martin Brovarney, Scott Jacobson, Danilo Nebalasca, Jorge Arguello, Blanca Gomez, Hiranmayee Kandala, Michelle Y. Ko, Lan Nguyen, Omar Robles, Grant Shibuya, Anton A. Shakhmin, Parcharee Tivitmahaisoon, Vi-Anh Vu, Ashkaan Younai, Mikhail Zibinsky, Babu Subramanyam, Daniel Poon, Mohsen Sabouri Ghomi, David J. Wustrow, Paul D. Kassner, George E. Katibah, Dirk G. Brockstedt. HPK1 inhibits CD8+ T cell effector gene expression following T cell activation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2654.

Correction: Inhibition of host Ogr1 enhances effector CD8+ T-cell function by modulating acidic microenvironment

O-GlcNAcylation promotes tumor immune evasion by inhibiting PD-L1 lysosomal degradation

Correction: Glucocorticoid impairs cell-cell communication by autophagy-mediated degradation of connexin 43 in osteocytes (Oncotarget (2016) 7 (26966-26978) DOI: 10.18632/oncotarget.9034)

Abstract 1179: A single-cell atlas of human gastric malignancy reveals CD8+ T cell rejuvenation as a mediator of immunotherapeutic response

Modulation Of Cd8(+) Memory Stem T Cell Activity And Glycogen Synthase Kinase 3 Beta Inhibition Enhances Anti-Tumoral Immunity In Gastric Cancer

Author Correction: An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity

Inhibition of O-GlcNAc transferase activates type I interferon-dependent antitumor immunity by bridging cGAS-STING pathway

Author Correction: A Next-Generation Tumor-Targeting IL-2 Preferentially Promotes Tumor-Infiltrating CD8+ T-cell Response and Effective Tumor Control

Targeting tumor O‐glycosylation modulates cancer–immune‐cell crosstalk and enhances anti‐PD‐1 immunotherapy in head and neck cancer

Correction: c-Myc-driven glycolysis polarizes functional regulatory B cells that trigger pathogenic inflammatory responses

Corrigendum: LYG1 Deficiency Attenuates the Severity of Acute Graft-Versus-Host Disease via Skewing Allogeneic T Cells Polarization Towards Treg Cells

Abstract 2654: HPK1 inhibits CD8+ T cell effector gene expression following T cell activation

Overcoming T cell dysfunction in acidic pH to enhance adoptive T cell transfer immunotherapy

Correction: An oncogenic viral interferon regulatory factor upregulates CUB domain-containing protein 1 to promote angiogenesis by hijacking transcription factor lymphoid enhancer-binding factor 1 and metastasis suppressor CD82

Correction to: NUPR1 promotes the proliferation and metastasis of oral squamous cell carcinoma cells by activating TFE3-dependent autophagy

Correction to: TGF-beta1 gene-modified, immature dendritic cells delay the development of inflammatory bowel disease by inducing CD4(+)Foxp3(+) regulatory T cells

Author Correction: Selenium–GPX4 Axis Protects Follicular Helper T Cells from Ferroptosis

Correction to: The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them

Correction: Infiltrating Mast Cells Increase Prostate Cancer Chemotherapy and Radiotherapy Resistances Via Modulation of P38/p53/p21 and ATM Signals.

Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing